Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57053
Type
ArticleCopyright
Open access
Sustainable Development Goals
10 Redução das desigualdadesCollections
Metadata
Show full item record35
CITATIONS
35
Total citations
35
Recent citations
8.14
Field Citation Ratio
2.35
Relative Citation Ratio
GENE THERAPY ACCESS: GLOBAL CHALLENGES, OPPORTUNITIES, AND VIEWS FROM BRAZIL, SOUTH AFRICA, AND INDIA
Author
Affilliation
Department of Medical and Molecular Genetics. Indiana University School of Medicine. Indianapolis, USA.
Molecular Carcinogenesis Program, Research, Coordination National Cancer Institute. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Presidency. Vice-Presidency Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Department of Molecular Medicine and Haematology. School of Pathology. Faculty of Health Sciences. University of the Witwatersrand. Johannesburg, South Africa.
Spark Therapeutics. Philadelphia, USA.
Faculty of Medicine. University of Southampton. UK & KJ Somaiya. Super Speciality Hospital and Research Centre. Mumbai, India.
Department of Biological Sciences and Bioengineering. Indian Institute of Technology Kanpur. Kapur, India.
Molecular Carcinogenesis Program, Research, Coordination National Cancer Institute. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Presidency. Vice-Presidency Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Department of Molecular Medicine and Haematology. School of Pathology. Faculty of Health Sciences. University of the Witwatersrand. Johannesburg, South Africa.
Spark Therapeutics. Philadelphia, USA.
Faculty of Medicine. University of Southampton. UK & KJ Somaiya. Super Speciality Hospital and Research Centre. Mumbai, India.
Department of Biological Sciences and Bioengineering. Indian Institute of Technology Kanpur. Kapur, India.
Abstract
Gene and cell therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. We reviewed the current status of gene and cell therapies in low- and middle-income countries and highlighted the need and current barriers to access. The state of product development in Brazil, South Africa, and India is discussed, including lessons learned from American Society of Gene and Cell Therapy (ASGCT)-sponsored virtual symposia in each of these countries.
Share